NovaBridge Biosciences Contract Liability (Deferred Revenue)
NovaBridge Biosciences (NBP) had Contract Liability (Deferred Revenue) of CNY 2.20 million as of 2023-12-31, per its 20-F filed 2024-04-30.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2024-04-30
- 2023-12-31: Contract with Customer, Liability, Current 2.20M CNY.
- 2022-12-31: Contract with Customer, Liability, Current 8.68M CNY.
- 2018-12-31: Contract with Customer, Liability, Current 14.15M CNY.
CNY
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2023-12-31 | 2.20M CNY 20-F · filed 2024-04-30 |
| 2022-12-31 | 8.68M CNY 20-F · filed 2024-04-30 |
| 2018-12-31 | 14.15M CNY 20-F · filed 2020-04-29 |
USD
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2023-12-31 | $310.00K 20-F · filed 2024-04-30 |
| 2022-12-31 | $1.26M 20-F · filed 2023-05-01 |